This post was originally published on this site An upcoming and free web-based documentary series explores why efforts to develop an Alzheimer’s therapy are so challenging and often end in failure, and how individuals can lower their disease risk. The multi-part series “Alzheimer’s — The Science of Prevention,” opens globally on Oct. 9 and runs through Oct.…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Addressing Unfair Judgment and Some Misconceptions About Caregiving
This post was originally published on this site It’s easy to pass judgment on others about what they may be doing wrong. Unfortunately, because of this, caregivers are often the targets of unfair scrutiny. Alzheimer’s caregivers are frequently the subjects of pointing fingers, and folks looking on from the cheap seats are quite opinionated. Here’s…
First Alzheimer’s Patients Dosed with PTI-125 in New Phase 2b Clinical Trial
This post was originally published on this site The first two patients with Alzheimer’s disease have been dosed with Cassava Sciences’ investigational small molecule PTI-125 in a new Phase 2b clinical study. PTI-125 is a small molecule that has been designed to bind to an abnormal form of a protein called Filamin A (or FLNA),…
Electromagnetic Device Improves Cognition in Alzheimer’s Patients, Small Study Finds
This post was originally published on this site NeuroEM Therapeutics‘s MemorEMTM — a head-worn device that uses electromagnetic waves — has shown promising results in a preliminary clinical trial of people with mild-to-moderate Alzheimer’s disease. Seven of eight participants demonstrated improved memory after two months of treatment. The results, “A Clinical Trial of Transcranial Electromagnetic…
Phase 3 Trials of Elenbecestat in Early Alzheimer’s Stopped for Lack of Benefit, Eisai and Biogen Say
This post was originally published on this site Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This decision was based on a safety review conducted by an independent data monitoring committee that found an unfavorable…
Effective Responses to the Problem of Elder Abuse
This post was originally published on this site For millions of Americans, elder abuse is an unfortunate consequence of aging. The National Council on Aging (NCOA) estimates that one in 10 seniors ages 60 and older have been abused in the U.S. Physical abuse is just one form of mistreatment that some elderly people endure…
Alzheimer’s Vaccine Found Safe, Effective in Patients with Mild Forms of the Disease, Phase 2 Study Finds
This post was originally published on this site AXON Neuroscience’s investigational AADvac1 vaccine against tau protein, a hallmark of Alzheimer’s disease, was found safe and effective at lessening signs of neurodegeneration in patients with mild Alzheimer’s, according to the results of a Phase 2 trial. Among younger study participants, the vaccine also seemed to improve…
Bryostatin-1 Fails to Ease Dementia in Moderate-to-Severe Alzheimer’s Patients in Phase 2 Trial
This post was originally published on this site An investigational Alzheimer’s treatment called bryostatin-1 failed to meet its primary goal — lesser evidence of dementia in people with more severe disease — in a Phase 2 clinical trial, Neurotrope, the company developing the therapy, announced in a press release. Bryostatin-1 is a molecule that activates…
FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for Fibromyalgia
This post was originally published on this site The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for…
PTI-125 Reduces Neurodegeneration After 28 Days of Treatment, Data Show
This post was originally published on this site PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of disease biomarkers, brain inflammation, and neurodegeneration after 28 days of treatment, top-line data from a Phase 2 trial show. “Based on these encouraging biomarker results, this new treatment could be…
Taking a Look at the Cognitive Assessment Disconnect
This post was originally published on this site In the time that it takes to read the first few paragraphs of this column, someone in the United States will develop Alzheimer’s disease. One person in the U.S. develops the illness every 65 seconds, according to a 2019 report. The Alzheimer’s Association indicates that just over…
ADvance II Study Testing Deep Brain Stimulation in Mild Alzheimer’s Started, Enrollment Ongoing
This post was originally published on this site The first patient enrolled in the ADvance II Study has been implanted with a deep brain stimulation (DBS) device to start treatment for mild Alzheimer’s disease. The study will evaluate the safety and effectiveness of stimulating the fornix (DBS-f) — a major inflow and output pathway in…